Literature DB >> 20237038

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

William C Kreisl1, Jeih-San Liow, Nobuyo Kimura, Nicholas Seneca, Sami S Zoghbi, Cheryl L Morse, Peter Herscovitch, Victor W Pike, Robert B Innis.   

Abstract

UNLABELLED: Permeability-glycoprotein (P-gp), an efflux transporter in several organs, acts at the blood-brain barrier to protect the brain from exogenous toxins. P-gp almost completely blocks brain entry of the PET radiotracer (11)C-N-desmethyl-loperamide ((11)C-dLop). We examined the ability of (11)C-dLop to quantify P-gp function in humans after increasing doses of tariquidar, an inhibitor of P-gp.
METHODS: Seventeen healthy volunteers had a total of 23 PET scans with (11)C-dLop at baseline and after increasing doses of tariquidar (2, 4, and 6 mg/kg intravenously). A subset of subjects received PET with (15)O-H(2)O to measure cerebral blood flow. Brain uptake of (11)C-dLop was quantified in 2 ways. Without blood data, uptake was measured as area under the time-activity curve in the brain from 10 to 30 min (AUC(10-30)). With arterial blood data, brain uptake was quantified with compartmental modeling to estimate the rates of entry into (K(1)) and efflux from (k(2)) the brain.
RESULTS: Brain uptake of radioactivity was negligible at baseline and increased only slightly (approximately 30%) after 2 mg of tariquidar per kilogram. In contrast, 4 and 6 mg of tariquidar per kilogram increased brain uptake 2- and 4-fold, respectively. Greater brain uptake reflected greater brain entry (K(1)), because efflux (k(2)) and cerebral blood flow did not differ between tariquidar-treated and untreated subjects. In the subjects who received the highest dose of tariquidar (and had the highest brain uptake), regional values of K(1) correlated linearly with absolute cerebral blood flow, consistent with high single-pass extraction of (11)C-dLop. AUC(10-30) correlated linearly with K(1).
CONCLUSION: P-gp function at the blood-brain barrier in humans can be quantified using PET and (11)C-dLop. A simple measure of brain uptake (AUC(10-30)) may be used as a surrogate of the fully quantified rate constant for brain entry (K(1)) and thereby avoid arterial sampling. However, to dissect the function of P-gp itself, both brain uptake and the influx rate constant must be corrected for radiotracer delivery (blood flow).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237038      PMCID: PMC2856602          DOI: 10.2967/jnumed.109.070151

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  25 in total

1.  Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

Authors:  A Stewart; J Steiner; G Mellows; B Laguda; D Norris; P Bevan
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

Review 2.  Mechanisms of cancer drug resistance.

Authors:  Michael M Gottesman
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  Increased drug delivery to the brain by P-glycoprotein inhibition.

Authors:  A J Sadeque; C Wandel; H He; S Shah; A J Wood
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

4.  Several major antiepileptic drugs are substrates for human P-glycoprotein.

Authors:  Carlos Luna-Tortós; Maren Fedrowitz; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

Review 5.  Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications.

Authors:  P Kannan; C John; S S Zoghbi; C Halldin; M M Gottesman; R B Innis; M D Hall
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

6.  Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.

Authors:  Jian Zong; Gary M Pollack
Journal:  J Pharmacol Exp Ther       Date:  2003-04-29       Impact factor: 4.030

7.  P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.

Authors:  Jeih-San Liow; William Kreisl; Sami S Zoghbi; Neva Lazarova; Nicholas Seneca; Robert L Gladding; Andrew Taku; Peter Herscovitch; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

8.  Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.

Authors:  Nicholas Seneca; Sami S Zoghbi; Jeih-San Liow; William Kreisl; Peter Herscovitch; Kimberly Jenko; Robert L Gladding; Andrew Taku; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

9.  A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.

Authors:  Jame Abraham; Maureen Edgerly; Richard Wilson; Clara Chen; Ann Rutt; Susan Bakke; Rob Robey; Andrew Dwyer; Barry Goldspiel; Frank Balis; Olaf Van Tellingen; Susan E Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

10.  Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates.

Authors:  Karen A Kurdziel; Dale O Kiesewetter; Richard E Carson; William C Eckelman; Peter Herscovitch
Journal:  J Nucl Med       Date:  2003-08       Impact factor: 10.057

View more
  53 in total

1.  Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.

Authors:  M Bauer; M Zeitlinger; R Karch; P Matzneller; J Stanek; W Jäger; M Böhmdorfer; W Wadsak; M Mitterhauser; J P Bankstahl; W Löscher; M Koepp; C Kuntner; M Müller; Oliver Langer
Journal:  Clin Pharmacol Ther       Date:  2011-12-14       Impact factor: 6.875

2.  Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Authors:  Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

Review 3.  The controversial role of ABC transporters in clinical oncology.

Authors:  Akina Tamaki; Caterina Ierano; Gergely Szakacs; Robert W Robey; Susan E Bates
Journal:  Essays Biochem       Date:  2011-09-07       Impact factor: 8.000

4.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

Review 5.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 6.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Authors:  Robert W Robey; Paul R Massey; Laleh Amiri-Kordestani; Susan E Bates
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

Review 7.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

8.  Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity.

Authors:  Heli Savolainen; Albert D Windhorst; Philip H Elsinga; Mariangela Cantore; Nicola A Colabufo; Antoon Tm Willemsen; Gert Luurtsema
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

9.  The Inhibitor Ko143 Is Not Specific for ABCG2.

Authors:  Lora D Weidner; Sami S Zoghbi; Shuiyu Lu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Jan Mulder; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  J Pharmacol Exp Ther       Date:  2015-07-06       Impact factor: 4.030

Review 10.  Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Authors:  Stina Syvänen; Jonas Eriksson
Journal:  ACS Chem Neurosci       Date:  2012-12-04       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.